Latest News From Lumira Ventures

UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

admin Engage Therapeutics, Main Page, Portfolio News

– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …

Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020

admin Forbius (Formation Biologics), Main Page, Portfolio News

Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …

Edesa Biotech and Light chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

admin Edesa Biotech, Main Page, Portfolio News, Press Release

TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwide …